The global vaccine adjuvants market size is calculated at USD 1.73 billion in 2024, grew to USD 1.77 billion in 2025 and is predicted to hit around USD 2.18 billion by 2034, expanding at a CAGR of 2.33% between 2024 and 2034. The North America vaccine adjuvants market size is evaluated at USD 730 million in 2024 and is expected to grow at a CAGR of 2.38% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Vaccine Adjuvants Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Vaccine Adjuvants Market Revenue and Volume, by Type, 2024-2034
8.1.1 Pathogen
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Adjuvant EMULSION
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Particulate
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Combination
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Vaccine Adjuvants Market Revenue and Volume, by Application, 2024-2034
9.1.1. Infectious DISEASE
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Cancer
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Vaccine Adjuvants Market Revenue and Volume, by Administrator, 2024-2034
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Intradermal
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Intranasal
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1.4. Intramuscular
10.1.4.1. Market Revenue and Volume Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Volume Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by Administrator (2021-2034)
12.1. GlaxoSmithKline plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agenus
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck KGaA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. InvivoGen
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. CSL Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Dynavax Technologies
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Croda International PLC
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. OZ Biosciences
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. SEPPIC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. SPI Pharma
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample